ArticleBMJ open2013
The economic burden of visual impairment and blindness: a systematic review.
Article in BMJ open, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Costs associated with retinopathy of prematurity: a systematic review and meta-analysis.BMJ open · 2022Pooled it
- The association between visual impairment and fatigue: a systematic review and meta-analysis of observational studies.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2019Pooled it
- Socioeconomic and physical health status changes after visual impairment in Korea using difference-in-difference estimations.Scientific reports · 2021Trial
- Visual rehabilitation of patients with corneal diseases.BMC ophthalmology · 2020Trial
- Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.Advances in therapy · 2017Trial
- An economic analysis of postoperative cataract consultation using remote self-assessment.PLOS digital health · 2026Article
- Direct and indirect costs associated with declining distance visual acuity: A nationwide longitudinal cost-of-illness study with 11-year follow-up.Acta ophthalmologica · 2026Observational
- Motion perception with visual prostheses.Progress in biomedical engineering (Bristol, England) · 2026Review
- Clinical efficacy and cost-effectiveness of four myopia control interventions in children: a single-center retrospective study.Scientific reports · 2026Observational
- The economic burden of diabetes-related visual impairment and blindness in Saudi Arabia.Health economics review · 2026Article
- The social and economic burden of retinopathy of prematurity: screening, treatment, and health policy perspectives in a transnational narrative review.Frontiers in pediatrics · 2026Review
- The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review.Health economics review · 2025Review
- Top causes of visual impairment, satisfaction with eye care services, and associated factors among visually impaired patients attending an eye care center in Ethiopia.Scientific reports · 2025Article
- Global, Regional, and National Burden of Blindness due to Diabetic Retinopathy, 1990-2021.Ophthalmology and therapy · 2025Article
- Cost-per-response of Acthar Gel versus standard of care for the treatment of noninfectious keratitis: a United States healthcare perspective.Journal of comparative effectiveness research · 2025Article
- International prevalence of tactile map usage and its impact on navigational independence and well-being of people with visual impairments.Scientific reports · 2025Article
- Unmasking the Hidden Morbidity of Ocular Diseases in Primary Care Through a Collaboration with Specialists in Remote Areas: A Cross-Sectional Study from Rural Crete, Greece.Diseases (Basel, Switzerland) · 2025Article
- Remote Eye Triage: Health Economic Perspectives on Resource Prioritization.Health services insights · 2025Article
- Low vision aids provision in an urban setting in Germany between 2014 and 2017: a regional population based study with healthcare claims data.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- The societal economic impact of vision impairment in adults 40 years and above: findings from the National Eye Survey of Trinidad and Tobago.Eye (London, England) · 2024Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesVisual impairment and blindness (VI&B) cause a considerable and increasing economic burden in all high-income countries due to population ageing. Thus, we conducted a review of the literature to better understand all relevant costs associated with VI&B and to develop a multiperspective overview.
designSystematic review: Two independent reviewers searched the relevant literature and assessed the studies for inclusion and exclusion criteria as well as quality. ELIGIBILITY CRITERIA FOR INCLUDED STUDIES: Interventional, non-interventional and cost of illness studies, conducted prior to May 2012, investigating direct and indirect costs as well as intangible effects related to visual impairment and blindness were included.
methodsWe followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement approach to identify the relevant studies. A meta-analysis was not performed due to the variability of the reported cost categories and varying definition of visual impairment.
resultsA total of 22 studies were included. Hospitalisation and use of medical services around diagnosis and treatment at the onset of VI&B were the largest contributor to direct medical costs. The mean annual expenses per patient were found to be US$ purchasing power parities (PPP) 12 175-14 029 for moderate visual impairment, US$ PPP 13 154-16 321 for severe visual impairment and US$ PPP 14 882-24 180 for blindness, almost twofold the costs for non-blind patients. Informal care was the major contributor to other direct costs, with the time spent by caregivers increasing from 5.8 h/week (or US$ PPP 263) for persons with vision >20/32 up to 94.1 h/week (or US$ PPP 55 062) for persons with vision ≤20/250. VI&B caused considerable indirect costs due to productivity losses, premature mortality and dead-weight losses.
conclusionsVI&B cause a considerable economic burden for affected persons, their caregivers and society at large, which increases with the degree of visual impairment. This review provides insight into the distribution of costs and the economic impact of VI&B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.